Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Luqa Acquires China Rights to Topical Antibiotic from Spain's Ferrer

publication date: Apr 12, 2019

Luqa Pharma, a Shanghai dermatology and aesthetics company, acquired greater China rights to a novel topical antibiotic aimed at impetigo from Barcelona's Ferrer. The two companies will collaborate to obtain China approval of Ozenoxacin (known by trade names Ozanex, Dubine and Xepi), which is already approved in the US and EU. Depending on the outcome of the regulatory process, Luqa could exercise a licensing option for further development and commercialization of Ozenoxacin. More details....

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China